医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Berry Genomics NextSeq CN500 Instrument and Non-Invasive Prenatal Testing Reagent Kit Receives Chinese FDA Premarket Clearance

2015年03月31日 PM10:19
このエントリーをはてなブックマークに追加


 

BEIJING & SAN DIEGO

Berry Genomics Co., Ltd. announced today that Hangzhou Berry Genomics, a subsidiary of Berry Genomics Co., Ltd., has received premarket clearance from the Chinese Food and Drug Administration (CFDA) for the NextSeq CN500, a high throughput sequencing instrument developed with Illumina (NASDAQ:ILMN) to meet Chinese clinical needs. Hangzhou Berry Genomics also received premarket clearance for its non-invasive prenatal testing (NIPT) detection kit for trisomies 13, 18 and 21.

The NextSeq CN500 utilizes Illumina’s sequencing by synthesis technology and was designed for operations in a clinical setting. Complementary with NextSeq CN500, Berry Genomics’ NIPT kit is based on a proprietary PCR-free protocol, which simplifies the complex NIPT sample preparation process to a two-step workflow in a single tube. The system can process up to 96 samples per instrument run.

“From original conception in 2007 to its current IVD products, NIPT has gone through an adoption process with unprecedented speed. Thanks to the tremendous support provided by the Chinese government and clinicians, China today is at the forefront of NIPT development,” said Daixing Zhou, Chief Executive Officer of Berry Genomics. “Illumina’s market-leading sequencing technology has earned its place as the gold standard in the industry. By being able to partner with Illumina to develop and deliver an instrument that is suitable for Chinese clinical laboratories, we hope to serve the Chinese population with the most advanced technologies available in the world.”

“We are excited about the premarket clearance of the NextSeq CN500 by the CFDA,” said Tristan Orpin, Senior Vice President & General Manager, Reproductive and Genetic Health, of Illumina. “We value the relationship with Berry Genomics, a leader in NIPT in China, and are honored to make contributions to improve the health of the Chinese population. We will continue collaborating with Berry Genomics to deliver the gold standard in sequencing-based clinical applications to the market.”

About Berry Genomics

Berry Genomics (www.berrygenomics.com) is a leading biotech company in China which develops and commercializes next-generation, sequencing-based integrated solutions for clinical applications, primarily in genetic testing and oncology testing. Berry Genomics pioneered non-invasive prenatal testing (NIPT) in China and is the leading provider of NIPT in China. Like NIPT, the products and technologies under development at Berry Genomics will address unmet needs of other genetic diseases and cancer.

About Illumina

Illumina is transforming human health as the global leader in sequencing- and array-based technologies. The company serves customers in a broad range of markets, enabling the adoption of genomic solutions in research and clinical settings. To learn how Illumina is unlocking the power of the genome, visit www.illumina.com and follow @illumina.

CONTACT

Berry Genomics Co., Ltd.
Media:
Jingjing Zhao
+86
10 84403068
zhaojingjing@berrygenomics.com
or
Illumina,
Inc.

Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer
Temple
858-882-6822
pr@illumina.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease